Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics and Oxytocin in ASD Children
NCT03337035Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2018
- Primary completion
- Oct 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lactobacillus plantarum PS128 and oxytocin nasal spray in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Social Responsiveness Scale Edition 2 at 28 weeks and Aberrant Behavior Checklist Edition 2 at 28 weeks. Started Dec 2018; status: completed.
02
Drugs
lactobacillus plantarum PS128oxytocin nasal spray
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03337035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03337035.